Viewing Study NCT00226330



Ignite Creation Date: 2024-05-05 @ 12:02 PM
Last Modification Date: 2024-10-26 @ 9:19 AM
Study NCT ID: NCT00226330
Status: TERMINATED
Last Update Posted: 2010-11-19
First Post: 2005-09-23

Brief Title: GALLEX 6 Study to Evaluate the Safety and Tolerability of Tesaglitazar in Patients With Type 2 Diabetes Mellitus
Sponsor: AstraZeneca
Organization: AstraZeneca

Study Overview

Official Title: A Double-Blind Multi-Centre Active-Controlled 15 30 and 45 mg Pioglitazone Long-Term Extension Study to Evaluate the Safety and Tolerability of Tesaglitazar 05 and 1 mg in Patients With Type 2 Diabetes Mellitus GALLEX 6
Status: TERMINATED
Status Verified Date: 2010-11
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: The development program has been terminated
Has Expanded Access: No
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: This is a parallel-group multi-center long-term extension study from the GALLANT 6 study to monitor the safety and tolerability of oral tesaglitazar compared with pioglitazone in patients with type 2 diabetes for up to 104 weeks of treatment The total duration including treatment and follow-up is 107 weeks
Detailed Description: None

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None